AstraZeneca Halts 895-Patient Volrustomig Lung Cancer Phase III Trial After Futility Review
Updated
Updated · XTB · Aug 17
AstraZeneca Halts 895-Patient Volrustomig Lung Cancer Phase III Trial After Futility Review
3 articles · Updated · XTB · Aug 17
Summary
AstraZeneca stopped the Phase III eVOLVE-Lung02 study of volrustomig plus chemotherapy in first-line metastatic non-small cell lung cancer after an independent monitoring review recommended discontinuation.
The IDMC found the regimen was unlikely to hit either dual primary endpoint—progression-free survival or overall survival—in patients with PD-L1-negative tumors, compared with pembrolizumab plus chemotherapy.
No new safety signals emerged, and AstraZeneca said it will work with investigators to maintain patient care and follow-up as the trial winds down.
The global study had enrolled 895 patients across 25 countries, targeting tumors with PD-L1 expression below 50%, while other Phase III volrustomig trials in cervical cancer, head and neck cancer, and mesothelioma continue.